"I’m more just mad at myself for getting too caught up in the record and not caught up enough in the sprint finish," the ...

Citius Pharmaceuticals shares are trading lower by 15% during Wednesday's session. The company announced a $3 million registered direct offering. The company will issue 743,496 shares of common ...

D. Boral Capital reiterated their buy rating on shares of Citius Pharmaceuticals (NASDAQ:CTXR – Free Report) in a report released on Tuesday morning,Benzinga reports. D. Boral Capital currently has a ...

In a report released yesterday, Michael Okunewitch from Maxim Group maintained a Buy rating on Citius Oncology (CTOR – Research Report), with a ...

D. Boral Capital upgraded Citius Pharmaceuticals (CTXR) to Buy from Hold with a $9 price target. Citius owns 90% of Citius Oncology (CTOR), which is close to commercializing Lymphir, an ...

CRANFORD, N.J., Jan. 8, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to ...

Fintel reports that on December 30, 2024, D. Boral Capital upgraded their outlook for Citius Pharmaceuticals (NasdaqCM:CTXR) from Hold to Buy. Analyst Price Forecast Suggests 121.74% Upside As of ...

Citius Pharmaceuticals (CTXR) and its oncology-focused subsidiary, Citius Oncology (CTOR), announced progress in preparations for the ...

Citius Pharma ( (CTXR)) has released its Q4 earnings. Here is a breakdown of the information Citius Pharma presented to its investors. Citius Pharmaceuticals, Inc. is a biopharmaceutical company ...

Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the ...